Recognizing the Significant Burden and Renewing a Treatment Options

Health Care Spending in Patients With Stage 3 and Stage 4 Pressure Injuries and Patients With Diabetic Foot Ulcers Treated Early With Clostridial Collagenase Ointment: A Retrospective Data Review Jeffrey D. Lehrman, Ankur Patel, Gary Delhougne The objective of this study is to estimate health care spending among patients with Stage 3 and Stage 4 pressure injuries (PIs) and patients with diabetic foot ulcers (DFUs) who experienced early (ie, within 30 days of index diagnosis) versus late (31 to 90 days of index diagnosis) initiation of CCO. Full Article


DFU: Advancing Practice Kathryn E. Davis, PhD; Lawrence A. Lavery, DPM, MPH At our presentation at SAWC Virtual, we evaluated the potential of several emerging treatments, such as point of care bacteria fluorescence, ultraviolet light, negative pressure wound therapy (NPWT) with irrigation, topical oxygen therapy, hyperspectral imaging, and laser therapy. Full Article


DFU Podcast: Giving Patients What They Deserve Steve Bergquist, MD, CWSP In this podcast, hosted by Steve Bergquist, MD, CWSP, joined by Robert Klein, DPM, FACFAS, CWS, and Emilia Krol, MD, who discuss the major changes to wound care and the management of peripheral arterial disease in diabetic patients, which has lead to a variety of approaches to treat diabetic foot wounds.


Full Podcast Diabetic Neuropathic Ulcers: Recognizing the Significant Burden and Renewing a Treatment Option Jeffery D. Lehrman, DPM, FASPS, MAPWCA, CPC The objectives of this presentation are as follows: establish the prevalence and impact of lower extremity diabetic neuropathic ulcers, review the components of good ulcer care, and present the first and only FDA-approved platelet-derived growth factor (PDGF) therapy for the treatment of lower extremity diabetic neuropathic ulcers. Full Webinar